{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:50:22Z","timestamp":1766087422534,"version":"3.48.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin Municipality","doi-asserted-by":"publisher","award":["22JCYBJC00700"],"award-info":[{"award-number":["22JCYBJC00700"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171338"],"award-info":[{"award-number":["82171338"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jneuroim.2025.578741","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T21:43:22Z","timestamp":1756676602000},"page":"578741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Treatment strategy for myasthenia gravis with GAD65-IgG associated neurological disorders: A case report"],"prefix":"10.1016","volume":"409","author":[{"given":"Xiao-Na","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Sheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2025.578741_bb0005","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2020-325300","article-title":"Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management","volume":"92","author":"Abboud","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2025.578741_bb0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41577-023-00911-8","article-title":"A guide to thymic selection of T cells","volume":"24","author":"Ashby","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0015","article-title":"Neural autoantibodies in cerebrospinal fluid and serum in clinical high risk for psychosis, first-episode psychosis, and healthy volunteers","volume":"12","author":"Bien","year":"2021","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/mus.22103","article-title":"The thymus in myasthenia gravis: site of \u201cinnate autoimmunity\u201d?","volume":"44","author":"Cavalcante","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2025.578741_bb0025","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1212\/WNL.57.5.780","article-title":"Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies","volume":"57","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2025.578741_bb0030","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa01167","article-title":"High-dose intravenous immune globulin for stiff-person syndrome","volume":"345","author":"Dalakas","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0035","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00415-023-11970-1","article-title":"Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome","volume":"271","author":"Di Stefano","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jneuroim.2015.03.009","article-title":"GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders","volume":"281","author":"Fouka","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0045","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0050","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0055","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0060","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0065","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41582-020-0359-x","article-title":"GAD antibodies in neurological disorders - insights and challenges","volume":"16","author":"Graus","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121364","article-title":"Antibodies to inhibitory synaptic proteins in neurological syndromes associated with glutamic acid decarboxylase autoimmunity","volume":"10","author":"Gresa-Arribas","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2025.578741_bb0075","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40263-023-01000-z","article-title":"Efgartigimod alfa in generalised myasthenia gravis: a profile of its use","volume":"37","author":"Heo","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jneuroim.2025.578741_bb0080","first-page":"17","article-title":"Stiff man syndrome and related conditions","author":"Hm","year":"2002","journal-title":"Move.t Disord.: Off. J. Move. Disord. Soc."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0085","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0090","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology--mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1750-1172-6-3","article-title":"Respective implications of glutamate decarboxylase antibodies in stiff person syndrome and cerebellar ataxia","volume":"6","author":"Manto","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/mus.25565","article-title":"GAD65 neurological autoimmunity","volume":"56","author":"McKeon","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2025.578741_bb0105","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/neurosci5020015","article-title":"Characterization of anti-GAD65-associated neurological syndromes: clinical features and antibody titers","volume":"5","author":"Moura","year":"2024","journal-title":"NeuroSci"},{"key":"10.1016\/j.jneuroim.2025.578741_bb0110","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000696","article-title":"Neurologic syndromes related to anti-GAD65: clinical and serologic response to treatment","volume":"7","author":"Mu\u00f1oz-Lopetegi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0115","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1563700","article-title":"Progressive encephalomyelitis with rigidity and myoclonus after thymectomy in a woman with myasthenia gravis","volume":"16","author":"Qin","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0130","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1093\/brain\/awn183","article-title":"Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association","volume":"131","author":"Saiz","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2025.578741_bb0135","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2025.578741_bb0140","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1196\/annals.1405.038","article-title":"IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies","volume":"1132","author":"Zinman","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557282500222X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016557282500222X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:43:25Z","timestamp":1766087005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016557282500222X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":28,"alternative-id":["S016557282500222X"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578741","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment strategy for myasthenia gravis with GAD65-IgG associated neurological disorders: A case report","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2025.578741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"578741"}}